Mike Tysons weird stem cell treatment has helped transform incredible body at 55 – Daily Star

Mike Tyson has claimed that he underwent stem-cell treatment several years ago, which transformed his body but left him feeling weird ever since".

Former heavyweight champion Tyson was one of the most physically intimidating boxers of all-time, boasting tremendous speed and devastating power throughout his career.

However, following his retirement from boxing in 2005, Tyson moved away from the sport entirely and began to gain weight.

This all changed several years ago, when Tyson made the decision to turn his life around and get back into fighting shape.

Alongside changing his diet and daily routine, Tyson recently stated that he underwent stem-cell therapy to aid his body transformation.

In recently resurfaced footage of an interview with LL Cool J on SiriusXM last year, via The Sun, Tyson told the rapper about undergoing the therapy, which aims to repair damaged cells within the body and treat or prevent illness.

"Yes. As they took the blood it was red and when it came back it was almost transfluid (sic), Tyson claimed.

"I could almost see through the blood, and then they injected it in me.

"And Ive been weird ever since, Ive got to get balanced now."

Who do you want to see Mike Tyson fight next? Let us know in the comments section below.

Since undergoing his incredible body transformation, Tyson has returned to boxing with incredible results.

He recently competed for the first time in over a decade-and-a-half in an exhibition bout against fellow legend Roy Jones Jr. While Jones looked out of shape, Tyson looked in peak condition.

While the bout was deemed a draw, Tyson won the bout in most viewers eyes and impressed throughout the contest.

After the pay-per-view success of his bout with Jones Jr, Iron Mike is expected to return to the ring again, either later this year or early next year.

An opponent has not yet been announced, however, Tyson has been training intensely with coach Rafael Cordeiro and looks ready for another fight very soon.

Get your hands on your club's special edition 2021/22 annual. Find out more here.

Visit link:
Mike Tysons weird stem cell treatment has helped transform incredible body at 55 - Daily Star

Acute Monocytic Leukemia: Causes, Symptoms, and Treatment – Healthline

Leukemia is a group of cancers that affect your bone marrow and cause your body to produce abnormal blood cells. Acute myeloid leukemia (AML) is the most common type of leukemia in adults and accounts for about 4 out of 5 adult cases.

Acute monocytic leukemia (AML-M5) is a subtype of AML, in which at least 80 percent of the affected blood cells are a type of white blood cell called monocytes. Half of the people diagnosed with AML M5 are older than age 49.

AML-M5 causes similar symptoms in the early stages as other types of leukemia. These symptoms include:

In this article, we take a look at how acute monocytic leukemia differs from other leukemias, how its treated, and whats the outlook.

Leukemias develop in bone marrow stem cells that produce blood cells. Theyre classified based on the type of blood cells affected and how quickly the disease progresses. Heres how each main type is broken down:

AML is a type of leukemia that develops quickly (acute) and affects myeloid cells (myeloid).

AML-M5 is a subtype of AML that mainly affects the growth of monocytes. Monocytes have the potential to become two other types of white blood cells called macrophages and dendritic cells.

According to the National Cancer Institute, AML-M5 is diagnosed when more than 20 percent of white blood cells are abnormal or not fully developed, and more than 80 percent of the abnormal cells are monocytes or cells derived from monocytes.

Like many types of cancer, its not entirely clear why AML-M5 develops in some people and not others. However, it has been linked to certain genetic mutations.

In a 2019 study, genetic mutations were detected in 83.3 percent of people with AML-M5. The mutations FLT3-ITD and NRAS were most common.

Symptoms of AML-M5 are similar to those of many other forms of leukemia. Symptoms like fatigue or feelings of weakness are general and can have many potential causes.

Some other possible symptoms of AML-M5 include:

Many of the symptoms of leukemia are general and can have many different causes. A healthcare professional will likely want to order a blood test to look for signs of the disease, such as a high number of abnormal white blood cells or a low blood count.

If your blood test reveals signs of leukemia, youll likely be referred to a doctor called a hematologist, who specializes in blood conditions.

The next part of your diagnosis will likely involve a bone marrow biopsy, usually from your hip bone. During this procedure, an anesthetic will be applied to your skin. Then, the doctor will use a thin needle to remove bone marrow from the center of your hip bone.

The procedure usually takes about 20 to 30 minutes and shouldnt be painful. Your sample will then be taken to a lab for analysis.

Other supportive tests may be used to collect more information about the specific type of AML you have, how far it has progressed, and what the best treatment option may be.

AML-M5 can be difficult to treat due to a limited amount of research on the best way to manage this specific type of AML.

Treatment for most forms of AML involves multidrug chemotherapy and bone marrow transplants. The amount of chemotherapy you can receive depends on factors such as your age and overall health.

The goal of induction chemotherapy is to kill as many cancer cells as possible. It involves taking a high dose of chemotherapy drugs that target cancer cells. Unfortunately, it also targets healthy cells in your body that divide rapidly, such as blood stem cells, skin cells, and gastrointestinal cells.

The strength of the chemotherapy you can handle may depend on your age or overall health. Chemotherapy drugs are highly toxic to your bone marrow and can cause bleeding complications, kidney failure, and other potentially serious side effects, so your doctor will run tests often to check your health.

The chemotherapy drug cytarabine and either daunorubicin or idarubicin are often used in a 7+3 regimen. This mean you get cytarabine through an IV for 7 days, along with a small dose of one of the other medications on the first 3 days.

Here are a few other variations in the way this treatment might work:

Typically, youll stay in the hospital during the induction phase. If there are still signs of cancer in your body at the end of treatment, you may need another round of chemotherapy.

After going into remission, meaning the cancer is no longer detectable, most people undergo additional chemotherapy to target any remaining undetectable cancer cells and keep the cancer from coming back.

Young and healthy individuals often undergo several cycles of high-dose cytarabine combined with bone marrow transplants. Older adults or those with other coexisting health conditions may receive lower doses of cytarabine or other chemotherapy drugs.

High doses of chemotherapy damage the cells in your bone marrow that produce blood cells. A bone marrow transplant replaces damaged cells with healthy ones. Two types of transplants may be performed:

When a suitable donor is available, allogeneic transplants are the preferred procedure.

The outlook for people with AML-M5 has not been clearly established. However, it is known that it often progresses quickly when left untreated.

When your body makes too much of a protein called differentiation inhibitory factor, it may be linked to a less promising prognosis in some people.

About 40 percent of people with AML-M5 have a mutation in their Flt3 gene, which also may be associated with a less favorable outcome.

In a 2020 study, researchers found the 5-year overall survival rate was 46 percent in a group of 132 children with AML-M5. The overall survival rate was lowest in children under 3 years old.

Researchers are continuing to study AML-M5 in clinical trials to find the best way to treat this type of leukemia. Its likely the survival rate will continue to improve with time and new data.

Many types of leukemia that used to have high mortality rates are now very treatable, thanks to medical advancements. You can ask your doctor about clinical trials in your area, or you can search for them yourself from the U.S. National Library of Medicine.

Originally posted here:
Acute Monocytic Leukemia: Causes, Symptoms, and Treatment - Healthline

UC Davis and the School of Medicine set new records in research funding – UC Davis Health

The University of California, Davis, set a new record for external research funding, receiving $968 million in awards in the fiscal year 2020-21, up $27 million from the previous record set last year. A major reason for this years growth was increased funding related to medicine and public health.

Professors Diana Farmer and Aijun Wang are collaborating to develop a stem cell treatment for spina bifida. (2019)

The School of Medicine received the largest increase in funding, up $92 million from the previous year, for a total of $368 million. Funding related to COVID-19 research totaled $42 million for the year. Studies in this area are providing critical insight into testing, vaccines, treatments and social impacts.

We are very proud of our researchers at the School of Medicine who rose to the challenge and expanded their groundbreaking work in the face of the pandemic, said Allison Brashear, dean of the UC Davis School of Medicine. All our research teams have shown great agility and collaboration across disciplines, quickly responding to emerging needs to prevent transmission and find treatments and vaccines to combat COVID-19, while also offering patients life-saving clinical trials in areas involving stem cell treatments, cancer and neuroscience, among many others.

Brashear noted that the School of Medicines clinical trials grew by 63% in the last year to $98 million.

The College of Agricultural and Environmental Sciences ($153 million), School of Veterinary Medicine ($83 million), College of Engineering ($80 million) and College of Biological Sciences ($58 million) rounded out the top five recipients.

This achievement reflects the unwavering commitment of our research community and their passion to address important societal needs during a year when operations were constrained due to the COVID-19 pandemic, Chancellor Gary S. May said. The societal impact of UC Davis research is far-reaching, spanning geographical boundaries and catering to diverse populations and needs.

The awards enable a broad range of research on topics including advancing human and animal health, protecting our planet and food supply and enabling a more resilient society.

The largest award, $51 million from the Department of Health and Human Services Centers for Disease Control and Prevention, went to Marc Schenker, distinguished professor of Public Health Sciences, to improve public health outcomes for all Californians by providing proper disease surveillance and prevention.

The federal government remains the largest provider of funding at $514 million, up $37 million from last year. The second leading source came from the state of California at $164 million, up $32 million. Funding from industry made up the third highest source, totaling $116 million, up $31 million.

UC Davis researchers received a total of 18 NSF CAREER Awards, a record for the university. These prestigious grants are offered to early-career faculty who have the potential to serve as academic role models in research and education and to lead advances in the mission of their department or organization.

Collaborative research bringing experts together from different fields of study continues to attract significant funding. These joint efforts often focus on addressing complex, large-scale challenges that require expertise from many perspectives.

We continue to see how multidisciplinary research provides a distinct advantage in tackling multifaceted issues, said Prasant Mohapatra, vice chancellor for Research at UC Davis. As one of the most academically comprehensive universities in the world, UC Davis offers a unique environment to solve these complex issues by bringing together experts from across our campuses.

Notable multidisciplinary awards include a $16 million grant from the National Institute of Mental Health for the UC Davis Conte Center to explore how infections in pregnancy lead to disorders in offspring. Principal investigators on this grant are Kimberly McAllister and Cameron Carter.

The Interdisciplinary Research and Strategic Initiatives division within the Office of Research offers support and resources to help teams advance their programs. Some of the notable interdisciplinary research projects include the work of Sheryl Catz, professor at the UC Davis Betty Irene Moore School of Nursing. Catz received $225,000 from the NIH National Cancer Institute for a project to improve the reach and effectiveness of smoking cessation services targeted to veterans living with HIV.

Diana Farmer, professor and chair in the Department of Surgery at UC Davis Health, also received $9 million from the California Institute for Regenerative Medicine (CIRM). Farmer is the principal investigator of the clinical trial, known formally as The CuRe Trial a cellular therapyfor in utero repair of myelomeningocele which uses stem cells before birth to treat the most serious form of spina bifida.

This story was originally written by Neelanjana Gautam and published here.

Note: Where funds are awarded up-front to cover several years, the money is counted in the first year the award was received. Incrementally funded awards are counted as authorized in each year. Reports are based on the principal investigators home school or college.

See the article here:
UC Davis and the School of Medicine set new records in research funding - UC Davis Health

NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer – Cancer Network

The National Comprehensive Cancer Network (NCCN) has announced a significant update to the guidelines for COVID-19 vaccine administration, including a third dose, in patients with cancer, according to a press release issued by the organization.1

The recommendation indicated that several groups of individuals should be eligible for a third dose of the COVID-19 vaccine, including those with new or recurring solid tumors within 1 year of their initial vaccine dose regardless of therapy, as well as those with active hematologic malignancies. Patients who have received a stem cell transplant (SCT) or engineered cellular therapy such as CAR T-cell therapy within the past 2 years should also eligible, as well as those who are recipients of SCT on immunosuppressive therapy or with a history of graft-versus-host disease regardless of when the transplant took place.

COVID-19 can be very dangerous, especially for people living with cancer, which is why were so grateful for safe and effective vaccines that are saving lives, Robert W. Carlson, MD, chief executive officer of the NCCN, said in a press release. Our organization exists to improve the lives of people with cancer; we have a long track record for making recommendations that improve quality and length of life. We want our patients to live the longest and best lives possible, which means following the science on vaccination and mask-wearing.

The NCCN COVID-19 Vaccine Advisory Committee consists of multidisciplinary physicians across the NCCNs Member Institutions. In particular, the committee includes experts in infectious diseases, vaccine development and delivery, cancer management, and medical ethics. The recommendations, which are based on available evidence and expert consensus, have been utilized globally to aid in making management decisions over the course of the COVID-19 pandemic.

When it comes to peoples safety, we have to take every precaution, Steve Pergam, MD,

MPH, associate professor of the Vaccine and Infectious Disease Division at Fred Hutchinson

Cancer Research Center and infection prevention director at Seattle Cancer Care Alliance, as well as the co-leader of the NCCN COVID-19 Vaccination Advisory Committee, said in a press release. That means even after a third dose of vaccine, we still recommend immunocompromised peoplesuch as those undergoing cancer treatmentcontinue to be cautious, wear masks, and avoid large group gatherings, particularly around those who are unvaccinated. All of us should do our part to reduce the spread of COVID-19 and get vaccinated to protect those around us from preventable suffering.

Additional recommendations from the updated guidelines suggest that all eligible caregivers and close contacts of those with cancer should be immunized whenever possible.2 The use of all vaccines with FDA approval or emergency use authorizationincluding the Pfizer/BioNTech BNT162b2 mRNA vaccine (Comirnaty), the Moderna mRNA-1273 SARS-CoV-2 vaccine, and the Janssen Ad26.COV2.S Adenovirus vector vaccineis recommended in eligible patients by the committee.

Those who are receiving allogeneic or autologous SCT or CAR T-cell therapy will need to wait at least 3 months post-therapy before receiving the vaccine. Patients with hematologic malignancies, including those receiving cytotoxic chemotherapy such as cytarabine and anthracycline-based induction regimens for acute myeloid leukemia, need to delay inoculation until absolute neutrophil count recovery. Those who are experiencing marrow failure from their disease and/or are expected to have limited or no recovery from their therapy as well as those who are receiving long-term maintenance are able to receive the vaccine once it is available.

In solid tumors, the vaccine may be received once available for those who are undergoing treatment with cytotoxic chemotherapy, targeted therapy, checkpoint inhibitors, and other immunotherapy or radiation therapy. Those who are undergoing major surgery need to wait a few days following their surgical procedure before getting the vaccines.

The Center for Disease Control (CDC) currently recommends a third dose of the mRNA COVID-19 vaccines for individuals who are moderately to severely immunocompromised. This includes:

The CDC recommends that a third dose of the mRNA COVID-19 vaccine should be given at a minimum of 4 weeks following the second dose of either the Moderna or Pfizer vaccines. Notably, although preliminary data indicate that a third dose could augment antibody titers in an immunocompromised population of patients, those who have been diagnosed with cancer continue to be at a higher risk for infection with COVID-19 and COVID-19related complications. Even with the additional dose, infection is still possible meaning that precautions such as avoiding crowds and wearing a mask are recommended.

More here:
NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer - Cancer Network

DHEC Supports Awareness and Education during National Sickle Cell Awareness Month – SCDHEC

FOR IMMEDIATE RELEASE: Aug. 30, 2021

COLUMBIA, S.C. Sickle cell disease is a serious genetic disorder that impacts many families around the country and around the world. The South Carolina Department of Health and Environmental Control (DHEC) supports the annual recognition of September as National Sickle Cell Awareness Month to help focus attention on the need for further research and treatment of sickle cell disease.

As the most common inherited blood disorder in the United States, sickle cell disease (SCD) currently affects approximately 100,000 Americans, including more than 4,000 South Carolinians who have the disease. Complications from SCD include pain attacks that can cause the individual to need hospitalization. Other potentially life-threatening complications include infections, stroke, and organ damage.

Because symptoms and complications of SCD can vary, treatment options are different for each person depending on their symptoms. The only known cure for SCD is bone marrow or stem cell transplant.

Sickle cell disease can be a debilitating and life-threatening disease for those who have it, and it can also affect the lives of their family and friends, said Dr. Brannon Traxler, DHEC Public Health Director. While September is National Sickle Cell Awareness Month, increasing public knowledge about sickle cell should be a year-long initiative.

The theme of this years monthly recognition is Sickle Cell Matters, which underscores the need to raise awareness about the daily struggles of those living with SCD as well as the need to address the stereotypes and stigmas associated with people who have the disorder.

Babies are born with SCD; it isnt a disease that someone can develop later in life. In people who are born with SCD, both copies of a hemoglobin gene are abnormal. A person born with one abnormal copy of the gene and one normal copy has "sickle cell trait." People with sickle cell trait usually don't have symptoms although in rare cases they can experience complications of SCD like pain crises. When two people with sickle cell trait have a child, there is a 25-percent chance the child will have SCD. Even if only one parent has a sickle cell trait, their child could still have an increased risk of inheriting a type of sickle cell disease.

Blood tests can confirm whether a person has sickle cell trait or SCD, and the disorders are commonly detected during newborn health screenings.

SCD disproportionally affects those with African ancestry or who identify as Black. The disease also can be found in anyone with genetic makeup from a part of the world where malaria is more widely spread, such as India, South America and Central America.

South Carolina has a Sickle Cell Disease State Plan developed by a group of dedicated partners who work to help mitigate this life-threatening disorder, said Dr. Traxler. We can all help increase awareness about sickle cell disease by sharing education and information within our communities, especially in minority or underserved communities that may struggle with access to routine health care.

In 2017, South Carolina established the South Carolina Sickle Cell Disease Advocacy Team, which remains focused on one common goal to improve the treatment and care received by individuals and their families who have sickle cell disease.

DHEC provides a printable sickle cell disease flyer available for anyone here. Organizations can order printed copies of the flyer for distribution by placing an order here. Learn more about the disease at cdc.gov/sicklecell.

###

About the South Carolina Sickle Disease Advocacy Team Members of the South Carolina Sickle Cell Disease Advocacy Team (SCSCDAT), who came together to develop the South Carolina Sickle Cell Disease State Plan, include physicians, hematologists, government agencies non-profit organizations, healthcare management organizations and individuals living with SCD and their family members.

Media Contacts:

COBRA Sickle Cell Program http://www.cobraagency70.com/home.html sicklecell@cobraagency70.com 843-225-4870

Louvenia D. Barksdale Sickle Cell Anemia Foundation http://www.ldbarksdalesc.org/ ldbarksdalesc@gmail.com 864-582-9420

James R Clark Memorial Sickle Cell Foundation http://www.jamesrclarksicklecell.org office@jamesrclarksicklecell.org 803-799-6471

Orangeburg Area Sickle Cell Anemia Foundation orangeburgsickle@gmail.com 803-534-1716

The B Strong Group thebstronggroup.org thebstronggroup@gmail.com 803-875-1266

DRE 365 (Dream Reach Empower) dre365sc@gmail.com 803-759-0700

Here is the original post:
DHEC Supports Awareness and Education during National Sickle Cell Awareness Month - SCDHEC

The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation – DocWire News

This article was originally published here

Gut Microbes. 2021 Jan-Dec;13(1):1966262. doi: 10.1080/19490976.2021.1966262.

ABSTRACT

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is used for the treatment of hematologic cancers and disorders. However, graft-versus-host disease (GVHD) in which the donor immune cells attack the genetically-disparate recipient is a significant cause of morbidity. Acute GVHD is an inflammatory condition and the gastrointestinal system is a major organ affected but is also tied to beneficial graft-versus-tumor (GVT) effects. There is increasing interest on the role of the microbiome on immune function as well as on cancer progression and immunotherapy outcomes. However, there are still significant unanswered questions on the role the microbiome plays in GVHD progression or how to exploit the microbiome in GVHD prevention or treatment. In this review, concepts of HSCT with the focus on GVHD pathogenesis as well as issues in preclinical models used to study GVHD will be discussed with an emphasis on the impact of the microbiome. Factors affecting the microbiome and GVHD outcome such as obesity are also examined. The bridging of preclinical models and clinical outcomes in relation to the role of the microbiome will also be discussed along with possibilities for therapeutic exploitation.

PMID:34455917 | DOI:10.1080/19490976.2021.1966262

Visit link:
The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation - DocWire News

Global Cryopreservation Equipment Market Report 2021-2028 – Growing Acceptance for Regenerative Medicine & Increasing Needs of Biobanking…

DUBLIN--(BUSINESS WIRE)--The "Cryopreservation Equipment Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Type, Cryogen Type, Application, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Freezers Segment to Contribute Major Share to Cryopreservation Equipment Market

Cryopreservation Equipment Market to reach US$ 11,255.02 million by 2028 from US$ 5,798.82 million in 2021; it is estimated to grow at a CAGR of 9.9%

The report highlights the trends prevailing in the market along with the market drivers and deterrents. The factors such as growing acceptance for regenerative medicine and increasing needs of biobanking practices drive the market growth. However, stringent regulatory requirements hinder the cryopreservation equipment market growth.

Cryopreservation plays an important part in the field of regenerative medicine as it facilitates stable and secure storage of cells and other related components for a prolonged time. Regenerative medicine enables replacing diseased or damaged cells, tissues, and organs by retrieving their normal function through stem cell therapy.

Owing to the advancements in the medical technology, stem cell therapy is now being considered as an alternative to traditional drug therapies in the treatment of a wide range of chronic diseases, including diabetes and neurodegenerative diseases.

Moreover, the US Food and Drug Administration (FDA) has approved blood-forming stem cells. The blood-forming stem cells are also known as hematopoietic progenitor cells that are derived from umbilical cord blood. The growing approvals for stem cell and gene therapies are eventually leading to the high demand for cryopreservation equipment. Following are a few instances of stem cell and gene therapies approved by the FDA and other regulatory bodies.

Based on type, the cryopreservation equipment market is segmented into freezers, sample preparation systems, and accessories. In 2020, the freezers segment held the largest share of the market, and it is expected to register the highest CAGR during 2021-2028. In ultracold freezers, liquid nitrogen is used for the successful preservation of more complex biological structures by virtually seizing all biological activities.

The COVID-19 pandemic has had a mixed impact on the cryopreservation equipment market. Restricted access to family planning services as well as diverted focus of people due to economic uncertainties and recession, and disturbed work-life balance have led to rise in egg and embryo freezing activities at fertility clinics during the pandemic.

As a result, the rising use of cryopreservation equipment is boosting the market growth. Furthermore, supply chain disruption caused due to congestion of ports and disturbances in other transport means has substantially affected the distribution of cryopreservation equipment and other accessories.

Market players are launching new and innovative products and services to maintain their position in the cryopreservation equipment market. In May 2021, Stirling Ultracold has been acquired by BioLife Solutions, Inc for cell and gene therapies and the broader biopharma market. In return for all of Stirling's outstanding shares, BioLife issued 6,646,870 shares of ordinary stock.

Key Market Dynamics

Market Drivers

Market Restraints

Market Opportunities

Future Trends

The report segments the global cryopreservation equipment market as follows:

By Type

By Cryogen Type

By Application

By End User

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/tjgti5

Visit link:
Global Cryopreservation Equipment Market Report 2021-2028 - Growing Acceptance for Regenerative Medicine & Increasing Needs of Biobanking...

Operational Highlights and Financial Results for the Year Ended June 30, 2021 – GlobeNewswire

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the fourth quarter and full-year ended June 30, 2021 (FY2021).

During this calendar year we made significant progress in both regulatory and clinical outcomes for our lead product candidate, remestemcel-L, after experiencing a disappointing set-back last year said Silviu Itescu, Chief Executive of Mesoblast. We are pleased with recent recommendations by FDAs CBER to meet with the review team and address remaining CMC items for remestemcel-L in the treatment of steroid-refractory acute graft versus host disease in children. Additionally, our most recent meeting with the FDA has provided clarity on the pathway towards an emergency use authorization for remestemcel-L in the treatment of COVID ARDS.

Operational Highlights

Remestemcel-L Outcome of recent meeting with FDA on regulatory pathway for emergency use authorization in the treatment of COVID-19 ARDS:

Remestemcel-L in the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) in children:

Rexlemestrocel-L in the treatment of chronic heart failure and chronic low back pain:

Manufacturing

Financial Highlights

DETAILED CLINICAL ACTIVITIES FOR THE FISCAL YEAR FY2021

Remestemcel-L

Acute Respiratory Distress Syndrome due to COVID-19

Mesoblast recently presented results from the randomized controlled trial of remestemcel-L in 222 ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) at the biennial Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases conference hosted by the University of Vermont, Burlington, VT, and at the International Society for Cell & Gene Therapy (ISCT) Scientific Signatures Series event on Cell and Gene-Based Therapies in Lung Diseases and Critical Illnesses.

The presented data included improved respiratory function in patients treated with remestemcel-L, as well as 90-day survival outcomes showing remestemcel-L significantly reduced mortality by 48% at 90 days compared to controls in a pre-specified exploratory analysis of 123 treated patients under 65 years old. The trial had been halted after the third interim analysis since the 30-day primary endpoint would not be attained.

Key presentation findings were:

Mesoblast plans to move forward with an additional Phase 3 trial in COVID-19 ARDS with the next step being to agree with the FDA the final protocol and potency assay.

Inflammatory Bowel Disease Crohns Disease and Ulcerative Colitis

A randomized, controlled study of remestemcel-L delivered by an endoscope directly to areas of inflammation and tissue injury in up to 48 patients with medically refractory Crohns disease and ulcerative colitis commenced at Cleveland Clinic in October 2020. The investigator-initiated study is the first in humans using local cell delivery in the gut and will enable Mesoblast to compare clinical outcomes using this delivery method with results from an ongoing randomized, placebo-controlled trial in patients with biologic-refractory Crohns disease where remestemcel-L was administered intravenously.

Rexlemestrocel-L

Chronic Heart Failure

The results from the landmark DREAM-HF randomized controlled trial in 537 treated patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF) who received rexlemestrocel-L (REVASCOR) or control sham, demonstrated that a single dose of rexlemestrocel-L resulted in substantial and durable reductions in heart attacks, strokes, and cardiac deaths. The trials primary endpoint of reduction in volume overload related hospitalizations was not achieved. The results of this trial identify New York Heart Association (NYHA) class II HFrEF patients as the optimal target population for greatest rexlemestrocel-L treatment effect, and therefore a focus for developing rexlemestrocel-L in the largest market in heart failure.

The incidence of heart attacks and strokes were reduced by 60% over a median follow-up period of 30 months following a single dose of rexlemestrocel-L in the entire population of 537 treated patients. The incidence of death from cardiovascular causes was reduced by 60% in the 206 patients with NYHA class II disease, a significant reduction which was evident in both ischemic and non-ischemic subgroups as well as diabetic and nondiabetic patients.

The results also show that the NYHA class II patients in the control group, following an initial period of approximately 20 months of disease stability, progressed to cardiac death rates in-line with NYHA class III patients. NYHA class II patients treated with a single dose of rexlemestrocel-L did not show such cardiac death progression.

The combination of the three pre-specified outcomes of cardiac death, heart attack or stroke into a single composite outcome - called the three-point major adverse cardiovascular events (MACE) is a well-established endpoint used by the FDA to determine cardiovascular risk. Rexlemestrocel-L reduced this three-point MACE by 30% compared to controls across the entire population of 537 treated patients. In the NYHA class II subgroup of 206 patients, rexlemestrocel-L reduced the three-point MACE by 55% compared to controls.

Mesoblast expects feedback from the FDA in the next quarter on the potential pathway to US regulatory approval for rexlemestrocel-L in patients with chronic heart failure.

Chronic Low Back Pain due to Degenerative Disc Disease

The results from the randomized controlled trial of its allogeneic mesenchymal precursor cell (MPC) therapy rexlemestrocel-L in 404 enrolled patients with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to conventional treatments indicate that a single injection of rexlemestrocel-L+hyaluronic acid (HA) carrier may provide a safe, durable, and effective opioid-sparing therapy for patients with chronic inflammatory back pain due to degenerative disc disease, and that greatest benefits are seen when administered earlier in the disease process before irreversible fibrosis of the intervertebral disc has occurred. The trial's composite outcomes of pain reduction together with functional responses to treatment were not met by either MPC group.

The rexlemestrocel-L+HA treatment group achieved substantial and durable reductions in CLBP compared to control through 24 months across the entire evaluable study population (n=391) compared with saline controls. Greatest pain reduction was observed in the pre-specified population with CLBP of shorter duration than the study median of 68 months (n=194) and subjects using opioids at baseline (n=168) with the rexlemestrocel-L+HA group having substantially greater reduction at all time points (1, 3, 6, 12, 18 and 24 months) compared with saline controls. There was no appreciable difference in the safety of MPC groups compared to saline control over the 24-month period of follow-up in the entire study population. In subjects using opioids at baseline, the MPC+HA demonstrated a reduction in the average opioid dose over 24 months, while saline control subjects had essentially no change.

There is a significant need for a safe, efficacious, and durable opioid-sparing treatment in patients with chronic low back pain due to severely inflamed degenerative disc disease. Mesoblast has filed a request and expects to receive feedback from the FDA on the pathway to US regulatory approval in patients with chronic low back pain due to degenerative disc disease.

Intellectual Property

Mesoblast has an extensive patent portfolio with over 1,000 patents and patent applications across 77 patent families, and patent terms extending through 2041. These patents cover composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells, and provide strong commercial protection for our products in all major markets, including the United States, Europe, Japan and China. During the fiscal year Mesoblast has significantly expanded its patent portfolio, focusing on areas of its strategic commercial interests.

Licensing agreements with JCR, Grnenthal, Tasly and Takeda highlight the strength of Mesoblast's extensive intellectual property portfolio covering mesenchymal lineage cells. Mesoblast will continue to use its patents to prosecute its commercial rights as they relate to its core strategic product portfolio. When consistent with the Companys strategic objectives, it may consider providing third parties with commercial access to its patent portfolio.

DETAILED FINANCIAL RESULTS

Financial Results for the Year Ended June 30, 2021 (FY2021)

In August we entered into a contractual amendment to extend the interest-only period of its current senior debt facility to at least January 2022 and as a result no loan repayments will be required prior to January 2022. Mesoblast is in active discussions to refinance the facility.

We expect to recognize the existing US$21.9 million of remestemcel-L pre-launch inventory on the balance sheet if we receive FDA approval.

As a result of the above and other remeasurements on revaluation of assets and liabilities, the loss after tax for FY2021 was US$98.8 million compared to US$77.9 million for FY2020. The net loss attributable to ordinary shareholders was 16.33 US cents per share for FY2021, compared with 14.74 US cents per share for FY2020.

Conference Call

There will be a webcast today, beginning at 7.00pm EDT (Monday, August 30, 2021); 9.00am AEST (Tuesday, August 31). It can be accessed via: https://webcast.boardroom.media/mesoblast-limited/20210826/NaN61036c41df5665001c97fc67

The archived webcast will be available on the Investor page of the Companys website: http://www.mesoblast.com

About Mesoblast

Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Companys proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has completed Phase 3 trials of rexlemestrocel-L for advanced chronic heart failure and chronic low back pain. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Two products have been commercialized in Japan and Europe by Mesoblasts licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see http://www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

References / Footnotes

Forward-Looking Statements

This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of Mesoblasts preclinical and clinical studies, and Mesoblasts research and development programs; Mesoblasts ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblasts ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblasts product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblasts product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblasts ability to enter into and maintain established strategic collaborations; Mesoblasts ability to establish and maintain intellectual property on its product candidates and Mesoblasts ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblasts expenses, future revenues, capital requirements and its needs for additional financing; Mesoblasts financial performance; developments relating to Mesoblasts competitors and industry; and the pricing and reimbursement of Mesoblasts product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblasts actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:

See the original post:
Operational Highlights and Financial Results for the Year Ended June 30, 2021 - GlobeNewswire

Event to benefit 2 families with kids fighting cancer – Youngstown Vindicator

News

Aug 30, 2021

AUSTINTOWN Local Relay for Life Team M&M The Flamingo Mafia and the Ice House Inn are joining to present a family friendly even Sept. 19 to raise money for the families of two area children battling cancer. Dozens of businesses, entertainers and volunteers have signed on to help.

The day-long Family Fun Day will feature live bands, comedians, food vendors, an auction, childrens activities (dunk tank, bounce house, etc.) and more.

Hours are noon to 9 p.m. Tickets are $10 for general admission and $5 for children 12 and younger. There is no admission charge for children under 3.

Advance tickets are available at the Ice House Inn, 5516 W. Webb Road, Austintown, or by calling Rosa at 330-559-0465. Tickets also will be available for purchase at the door the day of the event.

Nora Sabella, 7, and Joey Gaskell, 4, each went through rigorous treatments after their initial diagnoses only for their families to later learn they had both relapsed.

So many of us have personally experienced the devastating impact cancer has on families. For these families to go through everything theyve already been through only to face this all over again is unimaginable, said Tracy Greene, member and spokesperson for Team Flamingo Mafia.

Our team wanted to do something to help anyway we can. One way is to try to alleviate some of the financial burden, if we can, to allow them to focus on taking care of their children and each other.

ABOUT NORA

Nora, a student St. Charles School, lives in Boardman with her dad and mom, Jeff and Amy Sabella, her big sister, Nina Sabella, and Pickles the dog. She is battling relapsed neuroblastoma.

She was first diagnosed with Stage 4, High Risk Neuroblastoma on Jan. 29, 2018. She went through six cycles of chemotherapy, a stem cell transplant, 12 radiation treatments, six courses of immunotherapy, and many surgeries at Akron Childrens Hospital. She finished with frontline treatment March 24, 2019.

Nora immediately started a vaccine trial at Nationwide Childrens Hospital. After nearly two years on the trial, a lesion was found in Noras abdomen during routine scans.

On Nov. 23, 2020, Nora had a second tumor resection surgery, and the family was devastated to learn that she had relapsed. While small, the lesion was attached to her renal artery and renal vein, making it impossible to remove 100 percent. Nora started chemotherapy and immunotherapy the following week.

As of April this year, she had completed five cycles and there is still a tiny spot visible with subtle growth. So Nora started an intense chemotherapy regimen on April 28. She had a reaction to one of the chemotherapy drugs the second day and coded after becoming unresponsive. But the toxicity was quickly reversed with medication.

Another cycle of intense chemotherapy followed. Scans showed no change, and it was decided to do surgery. This surgery was originally to remove her kidney, but the surgeon was able to remove the tumor and save the organ.

After a two-week recovery, Nora started her third cycle of intense chemotherapy in combination with radiation treatments. Scans are planned for four weeks after her last radiation treatment.

Nora said she hopes the bad guy is gone and that shell be considered in remission. With remission comes another year of treatment at Memorial Sloan Ketteringin New York City for a vaccine trial process that will take approximately one year to complete. The family will have to travel to NYC up to 10 times in that year. The vaccine trial is to help her body learn to fight the neuroblastoma on its own.

ABOUT JOEY

Joey lives in Austintown and is the son of Todd and Jessica Gaskell. He wasnt attending school but hopes to start this year.

He was diagnosed with pre-B cell acute lymphoblastic leukemia in October 2018 at just 18 months old. His initial treatment was supposed to be about two years but two weeks before the end of his treatment, it was discovered he had relapsed in his central nervous system.

Joey is currently in remission again after an intensive first month of relapse treatment followed by fout months of frequent hospital stays, clinic visits for chemo and transfusions.

His current relapse treatment plan will consist of intensive chemo and radiation for about one-and-a-half years with a lot of hospital stays.

We just hope to see the community give these children, these families, the support they desperately need, said team co-captain Rosa Sheets. Any and all proceeds from this event are going directly to these two families. We appreciate any help and support people in our community and beyond can and are willing to give. It will be a fun-packed, family- and kid-friendly day.

Today's breaking news and more in your inbox

COVID-19 cases are above 3,000 once more statewide. The Ohio Department of Health reported 3,091 new cases ...

YOUNGSTOWN An Emergency Forum on Violence II on Monday touched on what its organizer called the ...

The Vindicator is seeking nominations for Firefighter of the Year, but for the first time also is allowing the ...

YOUNGSTOWN In addition to police finding the body of a young woman on the roadway on Southern Boulevard ...

View original post here:
Event to benefit 2 families with kids fighting cancer - Youngstown Vindicator

Cryo-Cell International Announces Uplisting to The Nasdaq Capital Market – GlobeNewswire

Cryo-Cell International, Inc. (Symbol CCEL), The Leader In Cord Blood And Cord Tissue Cryopreservation Services, Today Announced That The Companys Common Stock Has Been Approved For Listing On The Nasdaq Capital Market (Nasdaq).

Trading to Begin August 31, 2021 with Current Ticker CCEL

MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International has met Nasdaqs stringent financial, liquidity and corporate governance listing requirements. As a result, Cryo-Cell will be listed on Nasdaq as of Tuesday, August 31st 2021. This is expected to improve the liquidity of Cryo-Cell common stock, broaden its institutional shareholder base and ultimately enhance long-term shareholder value.

Cryo-Cells Chairman of the Board and Co-Chief Executive Officer, David Portnoy, stated: I am pleased to announce Cryo-Cells uplisting to Nasdaq, a major financial milestone that the Company had been considering, as previously stated several months ago. I believe that the significant gap between Cryo-Cells current market valuation and our intrinsic value should narrow as our visibility in the investment community grows, and this is a step in that direction. Cryo-Cell International has transformed in 2021 from being a profitable cord blood bank to a fully integrated, biopharmaceutical company that is expected to provide much needed access to experimental treatments for patients at the upcoming Cryo-Cell Institute for Cellular Therapies.

About Cryo-Cell International, Inc.

Founded in 1989, Cryo-Cell International, Inc. is the worlds first private cord blood bank. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell International has a public banking program in partnership with Duke University. Cryo-Cells public bank has provided cord blood for more than 600 transplantations and operates cord blood donation sites across the U.S in prominent hospitals such as CedarsSinai Hospital in Los Angeles and Baptist Hospital in Miami. Cryo-Cells facility is FDA registered, cGMP-/cGTP-compliant and licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. Cryo-Cell owns the exclusive rights to PrepaCyte-CB, the industrys most advanced cord blood processing technology.

Cryo-Cells mission has been to provide clients with state-of-the-art cord blood and cord tissue cryopreservation services, raise awareness of the opportunity for expectant parents to bank or donate their babys cord blood and support the advancement of regenerative medicine. In February 2021, Cryo-Cell entered into a license agreement with Duke University that transformed Cryo-Cell into an autonomous, vertically integrated cellular therapy company that will be able to treat patients.

For more information, please visitIR.cryo-cell.com

Forward-Looking Statement

Statements herein the terms believes, intends, projects, anticipates, expects, and similar expressions as used are intended to reflect forward-looking statements of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the impact of the COVID-19 pandemic on our sales, operations and supply chain, the success of the Companys global expansion initiatives and product diversification, the Companys actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Companys future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Companys business, the success of the Companys initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Companys ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Companys umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.

For more information, please contact: Corporate Communications / Investor Relations Diane Glanz, Rph, PharmD. Telephone: +1 (813) 749-2195 Email: Investors@Cryo-Cell.com

Read the original post:
Cryo-Cell International Announces Uplisting to The Nasdaq Capital Market - GlobeNewswire